Literature DB >> 27544822

The St. Gallen surrogate classification for breast cancer subtypes successfully predicts tumor presenting features, nodal involvement, recurrence patterns and disease free survival.

Ines Vasconcelos1, Afsana Hussainzada2, Stefan Berger3, Ellen Fietze3, Jörg Linke3, Friederike Siedentopf2, Winfried Schoenegg4.   

Abstract

AIMS: To evaluate how the St. Gallen intrinsic subtype classification for breast cancer surrogates predicts disease features, recurrence patterns and disease free survival.
MATERIALS AND METHODS: Subtypes were classified by immunohistochemical staining according to St. Gallen subtypes classification in a 5-tyre system: luminal A, luminal B HER2-neu negative, luminal B HER2-neu positive, HER2-neu non luminal or basal-like. Data were obtained from the records of patients with invasive breast cancer treated at our institution. Recurrence data and site of first recurrence were recorded. The chi(2) test, analysis of variance, and multivariate logistic regression analysis were used to determine associations between surrogates and clinicopathologic variables.
RESULTS: A total of 2.984 tumors were classifiable into surrogate subtypes. Significant differences in age, tumor size, nodal involvement, nuclear grade, multicentric/multifocal disease (MF/MC), lymphovascular invasion, and extensive intraductal component (EIC) were observed among surrogates (p < 0.0001). After adjusting for confounding factors surrogates remained predictive of nodal involvement (luminal B HER2-neu pos. OR = 1.49 p = 0.009, non-luminal HER2-neu pos. OR = 1.61 p = 0.015 and basal-like OR = 0.60, p = 0.002) while HER2-neu positivity remained predictive of EIC (OR = 3.10, p < 0.0001) and MF/MC (OR = 1.45, p = 0.02). Recurrence rates differed among the surrogates and were time-dependent (p = 0.001) and site-specific (p < 0.0001).
CONCLUSION: The St. Gallen 5-tyre surrogate classification for breast cancer subtypes accurately predicts breast cancer presenting features (with emphasis on prediction of nodal involvement), recurrence patterns and disease free survival.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Breast cancer; Disease free survival; Immunohistochemical surrogates; Molecular subtypes; Nodal involvement; Recurrence

Mesh:

Substances:

Year:  2016        PMID: 27544822     DOI: 10.1016/j.breast.2016.07.016

Source DB:  PubMed          Journal:  Breast        ISSN: 0960-9776            Impact factor:   4.380


  28 in total

Review 1.  Protein biomarkers for subtyping breast cancer and implications for future research.

Authors:  Claudius Mueller; Amanda Haymond; Justin B Davis; Alexa Williams; Virginia Espina
Journal:  Expert Rev Proteomics       Date:  2018-01-03       Impact factor: 3.940

2.  Natural history of luminal A breast invasive ductal carcinoma in an elderly.

Authors:  Geok Hoon Lim; Samantha Piao Xue Tay; Mihir Gudi
Journal:  BMJ Case Rep       Date:  2018-04-17

3.  CCR2 Chemokine Receptors Enhance Growth and Cell-Cycle Progression of Breast Cancer Cells through SRC and PKC Activation.

Authors:  Min Yao; Wei Fang; Curtis Smart; Qingting Hu; Shixia Huang; Nehemiah Alvarez; Patrick Fields; Nikki Cheng
Journal:  Mol Cancer Res       Date:  2018-11-16       Impact factor: 5.852

Review 4.  Immunohistochemical Profile of Parathyroid Tumours: A Comprehensive Review.

Authors:  Romans Uljanovs; Stanislavs Sinkarevs; Boriss Strumfs; Liga Vidusa; Kristine Merkurjeva; Ilze Strumfa
Journal:  Int J Mol Sci       Date:  2022-06-23       Impact factor: 6.208

5.  Multisite Tumor Sampling Reveals Extensive Heterogeneity of Tumor and Host Immune Response in Ovarian Cancer.

Authors:  Sotirios Lakis; Vassiliki Kotoula; Georgia-Angeliki Koliou; Ioannis Efstratiou; Sofia Chrisafi; Alexios Papanikolaou; Pantelis Zebekakis; George Fountzilas
Journal:  Cancer Genomics Proteomics       Date:  2020 Sep-Oct       Impact factor: 4.069

6.  PD-1 and PD-L1 Expression in Indian Women with Breast Cancer.

Authors:  Kishan R Bharadwa; Kuheli Dasgupta; Suma Mysore Narayana; C Ramachandra; Suresh M C Babu; Annapoorni Rangarajan; Rekha V Kumar
Journal:  Eur J Breast Health       Date:  2021-12-30

7.  Neoadjuvant Chemotherapy Exerts Selection Pressure Towards Luminal Phenotype Breast Cancer.

Authors:  Giulia Galli; Giacomo Bregni; Stefano Cavalieri; Luca Porcu; Paolo Baili; Amash Hade; Francesca Di Salvo; Milena Sant; Roberto Agresti; Massimiliano Gennaro; Secondo Folli; Maria C De Santis; Biagio Paolini; Maria L Carcangiu; Filippo de Braud; Serena Di Cosimo
Journal:  Breast Care (Basel)       Date:  2017-12-12       Impact factor: 2.860

8.  Landscape of somatic mutations in different subtypes of advanced breast cancer with circulating tumor DNA analysis.

Authors:  Zongbi Yi; Fei Ma; Chunxiao Li; Rongrong Chen; Lifang Yuan; Xiaoying Sun; Xiuwen Guan; Lixi Li; Binliang Liu; Yanfang Guan; Haili Qian; Binghe Xu
Journal:  Sci Rep       Date:  2017-07-20       Impact factor: 4.379

9.  Prognostic and clinicopathological value of Twist expression in breast cancer: A meta-analysis.

Authors:  Weiqiang Qiao; Zhiqiang Jia; Heyang Liu; Qipeng Liu; Ting Zhang; Wanying Guo; Peng Li; Miao Deng; Sanqiang Li
Journal:  PLoS One       Date:  2017-10-09       Impact factor: 3.240

10.  Expression and function of the miR-143/145 cluster in vitro and in vivo in human breast cancer.

Authors:  Charles Johannessen; Line Moi; Yury Kiselev; Mona Irene Pedersen; Stig Manfred Dalen; Tonje Braaten; Lill-Tove Busund
Journal:  PLoS One       Date:  2017-10-26       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.